

Study: ENGOT-cx20 / MK-2870

A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-Line or Third-Line Treatment for Participants with Recurrent or Metastatic Cervical Cancer

MaNGO Sites:

Prov	City	Site	Principal Investigator	Active **
BS	Brescia	Spedali Civili	Germana Tognon	
FI	Firenze	Ospedale Careggi	Maria Cristina Petrella	
MB	Monza	Ospedale San Gerardo	Stefania Canova *	
MI	Milano	Istituto Europeo di Oncologia	Nicoletta Colombo	
MI	Milano	Istituto Nazionale dei Tumori	Francesco Raspagliesi	
PD	Padova	Istituto Oncologico Veneto	Giulia Tasca	
RE	Reggio Emilia	Arcispedale S. Maria Nuova	Alessandra Bologna	
TO	Torino	Ospedale Sant'Anna	Elisa Piovano	
TO	Torino	Ospedale Mauriziano	Annamaria Ferrero	R
LC	Lecco	Ospedale Manzoni	Antonio Ardizzioia	R

* MaNGO Principal Investigator

** MaNGO sites list: to be confirmed by Sponsor

R: backup sites